|
Re: Treatment after Kadcyla?
Jules
I contacted Genentech and it seems my reasoning was basically correct. The Emtansine attached to the Trastuzumab molecule causes the complex to bind tightly yo the receptor allowing a lower Trastuzumab (Herceptin) dose to have a definite anti-Her2Neu effect
The Herceptin (Traztuzumab) in Kadcyla is active anti Her2Neu drug not a carrier molecule. Maybe you can bring this up with your oncologist. He or she can call Genentech from the UK
Paul
|